Oruka Therapeutics (ORKA) Current Deferred Revenue (2010 - 2013)

Oruka Therapeutics' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $3000.0 for Q2 2013.

• In Q2 2013, Current Deferred Revenue fell 90.91% year-over-year to $3000.0; the TTM figure through Jun 2013 stood at $3000.0 (down 90.91% YoY), while the FY2012 annual figure was $16000.0, down 51.52% from the prior year.
• Current Deferred Revenue was $3000.0 for Q2 2013 at Oruka Therapeutics, down from $8000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $121000.0 in Q4 2010 to a low of $3000.0 in Q2 2013.
• Historically, Current Deferred Revenue has averaged $33600.0 across 4 years, with a median of $32500.0 in 2011.
• The sharpest annual moves came in 2012 and 2013: Current Deferred Revenue changed 0.0% in 2012, then plunged 90.91% in 2013.
• A 4-year view of Current Deferred Revenue shows it stood at $121000.0 in 2010, then tumbled by 72.73% to $33000.0 in 2011, then plunged by 51.52% to $16000.0 in 2012, then sank by 81.25% to $3000.0 in 2013.
• The last three Current Deferred Revenue figures came in at $3000.0 (Q2 2013), $8000.0 (Q1 2013), and $16000.0 (Q4 2012), per Business Quant data.